Clinical Trials Act 2011Section 9
9. Pharmacovigilance Committee
(1) There shall be a Pharmacovigilance Committee which shall
consist of –
(a) a Chairperson, who shall be a specialist in internal
medicine and a public officer;
(b) a specialist in paediatrics;
(c) a specialist in dermatology;
(d) a clinical pharmacologist or a senior lecturer in
pharmacology at the University of Mauritius;
(e) 2 hospital pharmacists, who shall be public officers;
(f) an occupational physician;
(g) a nursing officer holding a BSc degree in Nursing or an
equivalent qualification;
(h) the Chief Pharmacy Dispenser.
(2) The Chairperson and every other member, other than an ex officio
member, shall –
(a) be appointed by the Minister on such terms and conditions
as he thinks fit; and
(b) hold office for a period of 2 years and be eligible for
reappointment.
(3) Every member shall be paid such fees or allowances as the Minister
may determine.
Acts 2011 103
(4) The Pharmacovigilance Committee may, where it deems
necessary, co-opt other members but any co-opted member shall have no right to
vote.
(5) (a) Where the Chairperson is absent from any meeting, the
members present shall elect from amongst themselves a member to preside at the
meeting.
(b) At a meeting of the Pharmacovigilance Committee,
5 members shall constitute a quorum.
(c) Adecision of the Pharmacovigilance Committee shall be by
a simple majority of the members present and voting and, in the event of an
equality of votes, the Chairperson shall have a casting vote.
(d) Subject to this Act, the Pharmacovigilance Committee
may conduct its meetings and proceedings in such manner as it thinks fit.
(6) The Supervising Officer may designate such number of public
officers as the Pharmacovigilance Committee may require to assist it in the
performance of its functions.